But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

Bausch + Lomb is headed by Brent Saunders, a longtime pharmaceutical executive known for leading Allergan into a much ... antitrust issues given its Restasis has a 45% share of the prescription ...

Harrow's products compete against established generics, and it heavily relies on marketing and sales force expansion to drive ...

Allergan Aesthetics intends to develop onabotulinumtoxinA treatment for MMP in additional global markets and expand the use of BOTOX ® Cosmetic in the lower face. IRVINE, Calif., Sept.

Pfizer and Allergan have confirmed that they will merge in a $160 billion deal, with Ireland-domiciled Allergan acquiring the US pharma giant, and re-naming itself Pfizer. The deal is the biggest ...

IRVINE, Calif., Sept. 11, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that BOTOX ® Cosmetic (onabotulinumtoxinA) is now available for the treatment of ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.